$8.170
+0.676 (+8.28%)收盤時
SGMT 資訊
SGMT 事件
U.S. Personal Spending Increased 0.6% in August
The major averages had a mixed day after data showed inflation slowed last month. Inflation-adjusted U.S. personal spending increased 0.6% month-on-month in August, the most since March 2025, accelerating from a 0.1% rise in July. The core PCE price index, the Federal Reserve's preferred gauge of underlying inflation in the U.S. economy, increased by 0.2% from the previous month in August, less than market expectations of a 0.3% rise. From the previous year, the core PCE price index rose by 3%, below forecasts of 3.3%.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Boeinghad secured a 6th generation F/A-XX Strike Fighter deal for over $20BConagra Brandsreported upbeat Q1 results and reiterated its FY27 outlookJabilreported better-than-expected Q4 earnings and revenue and provided an upbeat core earnings outlook for Q1 and FY27HP Enterpriseraised its FY27 Networking revenue growth view and announced a $1.2B order from Vultr to deploy AMDHelios AI Rack by HPE systems at Vultr's cloud data center locationsRobinhoodannounced Robinhood Agents and extended equities trading to 24-72. WALL STREET CALLS:Modernadowngraded to Sell from Neutral at CitiTargetupgraded to Buy at HSBC on potential earnings upsideMobileyedowngraded to Equal Weight at BarclaysOppenheimer upgraded Niceas AI disruption fears ease, platform improvesFICOdowngraded to Neutral at BofA after FHFA removed "home field advantage"3. AROUND THE WEB:Xbox CEO Asha Sharma said the Microsoftgaming unit is "not for sale," NY Times reportsTSMCis looking into potentially investing in Texas to expand its chip production in the U.S., Reuters saysParamount Skydancehas been discussing to investors about the debt it will be selling to fund its Warner Bros. Discoverybuyout, but the longer it has been discussing, the more it has to pay, Bloomberg saysFordCEO Jim Farley said a supplier issue that affected F-150 pickup-truck output in recent days has been resolved, but the snag has impacted the company's Q3 wholesale numbers, Reuters reportsOpenAI employees warned executives months before a model-testing incident that its newest AI systems were not being adequately monitored or secured, but leadership prioritized meeting release timelines and did not add security protocols, NY Times reports4. MOVERS:Sagimet Biosciencesgained after reporting results from its Phase 3 ASC40-304 OLE trialMongoDBincreased after its board authorized an additional $1B in stock buybacksUiPathwas higher after expanding its partnership with SnowflakeLiquidiadropped after the U.S. District Court for the District of Delaware ruled that two of six '327 patent claims brought by United Therapeuticswere valid and infringed by LiquidiaGeneral Millswas lower after naming McNabb to succeed Harmening as CEO5. EARNINGS/GUIDANCE:FactSetreported Q4 results and provided guidance for FY27, with CEO Sanoke Viswanathan calling it a "strong" quarterCal-Maine Foodsreported Q1 results, with EPS and revenue lower year-over-yearConcentrixreported Q3 results and provided guidance for both Q4 and FY26Conduentprovided guidance for FY27 and FY28Workdayreaffirmed guidance for Q3 and FY27INDEXES:The Dow fell 443.87, or 0.86%, to 50,906.05, the Nasdaq gained 63.52, or 0.24%, to 26,861.06, and the S&P 500 declined 19.30, or 0.25%, to 7,651.54.
U.S. Personal Spending Increased 0.6% Month-on-Month in August
The S&P was higher near noon after new U.S. economic data showed inflation slowed last month. Inflation-adjusted U.S. personal spending increased 0.6% month-on-month in August, the most since March 2025, accelerating from a 0.1% rise in July. The core PCE price index, the Federal Reserve's preferred gauge of underlying inflation in the U.S. economy, increased by 0.2% from the previous month in August, less than market expectations of a 0.3% rise. From the previous year, the core PCE price index rose by 3%, below forecasts of 3.3%.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Boeinghad secured a 6th generation F/A-XX Strike Fighter deal for over $20BConagra Brandsreported upbeat Q1 results and reiterated its FY27 outlookJabilreported better-than-expected Q4 earnings and revenue and provided an upbeat core earnings outlook for Q1 and FY27HP Enterpriseraised its FY27 Networking revenue growth view and announced a $1.2B order from Vultr to deploy AMDHelios AI Rack by HPE systems at Vultr's cloud data center locationsRobinhoodannounced Robinhood Agents and extended equities trading to 24-72. WALL STREET CALLS:Modernadowngraded to Sell from Neutral at CitiTargetupgraded to Buy at HSBC on potential earnings upsideMobileyedowngraded to Equal Weight at BarclaysOppenheimer upgraded Niceas AI disruption fears ease, platform improvesFICOdowngraded to Neutral at BofA after FHFA removed "home field advantage"3. AROUND THE WEB:McDonaldsis using AI to guide its menu prices in the U.S. and certain global markets, Reuters reportsTSMCis looking into potentially investing in Texas to expand its chip production in the U.S., Reuters saysParamount Skydancehas been discussing to investors about the debt it will be selling to fund its Warner Bros. Discoverybuyout, but the longer it has been discussing, the more it has to pay, Bloomberg saysFordCEO Jim Farley said a supplier issue that affected F-150 pickup-truck output in recent days has been resolved, but the snag has impacted the company's Q3 wholesale numbers, Reuters reportsOpenAI employees warned executives months before a model-testing incident that its newest AI systems were not being adequately monitored or secured, but leadership prioritized meeting release timelines and did not add security protocols, NY Times reports4. MOVERS:Sagimet Biosciencesgains after reporting results from its Phase 3 ASC40-304 OLE trialMongoDBincreases after its board authorized an additional $1B in stock buybacksUiPathhigher after expanding its partnership with Snowflake)Mattelfalls after announcing the appointment of Roger Lynch as CEOGeneral Millslower after naming McNabb to succeed Harmening as CEO5. EARNINGS/GUIDANCE:FactSetreported Q4 results and provided guidance for FY27, with CEO Sanoke Viswanathan calling it a "strong" quarterCal-Maine Foodsreported Q1 results, with EPS and revenue lower year-over-yearConcentrixreported Q3 results and provided guidance for both Q4 and FY26Conduentprovided guidance for FY27 and FY28Workdayreaffirmed guidance for Q3 and FY27INDEXES:Near midday, the Dow was down 27.21, or 0.05%, to 51,322.71, the Nasdaq was up 284.71, or 1.06%, to 27,082.25, and the S&P 500 was up 44.81, or 0.58%, to 7,715.65.
Sagimet Biosciences Prices Offering of 8.75 Million Shares at $10.00 Each
Sagimet Biosciences announced the pricing of an underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so choose, in lieu of shares of Series A common stock, pre-funded warrants to purchase 2,750,010 shares of its Series A common stock at a price of $9.9999 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.0001 per share and are exercisable immediately. The gross proceeds from the offering are expected to be approximately $115M, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the offering are to be sold by Sagimet. The offering is expected to close on or about October 1, subject to the satisfaction of customary closing conditions. Leerink Partners, TD Cowen, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering. Canaccord Genuity, H.C. Wainwright & Co., Jones and Clear Street are acting as co-lead managers for the offering.
Sagimet Biosciences Reports Positive Results from Acne Clinical Trial
Sagimet Biosciences announced positive 52-week results from the Phase 3 ASC40-304 OLE clinical trial of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioScience in China. The results were presented at the European Academy of Dermatology and Venereology Congress, or EADV, in Vienna by Ascletis. Denifanstat is a once-daily oral small molecule fatty acid synthase, or FASN, inhibitor being developed by Ascletis as ASC40 in China where it holds an exclusive license to denifanstat, and by Sagimet in the rest of the world. The Phase 3 OLE clinical trial, ASC40-304, evaluated the long-term safety of denifanstat in patients with moderate to severe acne vulgaris who were previously enrolled in the 12-week randomized, double-blind, placebo-controlled Phase 3 ASC40-303 clinical trial, conducted in China by Ascletis. 240 patients rolled over into the OLE trial, for a total trial duration of up to 52 weeks. Denifanstat was generally well-tolerated in the OLE with patients receiving up to 52 weeks of exposure, with no permanent discontinuations of study drug due to adverse events and no drug-related serious adverse events among patients treated with denifanstat. Only two categories of treatment-related adverse events had an incidence of more than 5% over the 52-week period: dry skin in 7.1% and dry eye in 5.9%.
Sagimet Biosciences AURORA Trial to Start Enrollment in Q4
Sagimet Biosciences announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on track to initiate enrollment in Q4.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。






